Michael X. Repka, MD, of Wilmer Eye Institute, reviews the updated consensus statement regarding management of retinopathy of prematurity detailed in the 3rd edition of the International Classification of Retinopathy of Prematurity.
For patients with glaucoma and retinovascular disease, those who received 7 or more intravitreal injections after glaucoma surgery had improved rates of success, a study shows.
A study shows most infants with prethreshold type 2 retinopathy of prematurity did not need laser ablation after receiving dexamethasone drops.
Elevated IOP, cataracts are potential complications of corticosteroid therapy.
Researchers recommend close, monthly monitoring up to 9 months after CRAO.
Anti-VEGF treatments delivered in the office or in the operating room had equal rates of the complication, an analysis shows.
Study shows BCVA gains and fluid resolution in eyes treated with the anti-VEGF agent.
Researchers also identify potential risk factors associated with the complications.
The intravitreal injection also demonstrated superior visual gains than the drug-eluting implant.
Investigators report that continuous treatment is important to ensure that the benefits are not lost due to recurrent NV activity.”
